The GOG Foundation, Inc (GOG-F), Board of Directors recently announced the election of Thomas J. Herzog, MD, as its next President, succeeding Larry J. Copeland, MD, who has served in this role since 2017. Under Dr. Copeland’s leadership, the GOG-F has experienced unprecedented growth in its clinical trials program for gynecologic malignancies, particularly in GOG-Partners (GOG-P), including a greatly expanded clinical trials portfolio; further expansion and engagement of its investigator base; development of a clinical trial mentorship program; and multiple educational initiatives focused on novel agents, clinical trial design, and clinical trial execution. Dr. Herzog will serve as President-Elect of the GOG-F for 1 year. Dr. Copeland will remain in office until July 2023 and continue to be involved in the organization as Immediate Past President.
Thomas J. Herzog, MD
Larry J. Copeland, MD
Dr. Herzog brings to this position a comprehensive background in clinical trials and the related business aspects. A gynecologic oncologist and member of the Board of Directors of GOG-F, he has served as Treasurer of GOG-F for the past 8 years and is Associate Director of the GOG-P program. He is currently Deputy Director of the University of Cincinnati Cancer Center and Paul & Carolyn Flory Professor in the Department of Obstetrics and Gynecology at the University of Cincinnati.
Supporting the Mission
“I am incredibly humbled and deeply honored to be elected as President-Elect of the GOG-F,” Dr. Herzog said. “I want to thank the Nominating Committee and Foundation Board for their support. I am so excited to work with such an outstanding and dedicated team. I especially want to thank Dr. Copeland for his mentorship throughout my career as well as his outstanding vision and leadership of our organization during his tenure. He has created a culture that places the best interests of our patients as the central focus in the mission to deliver tomorrow’s care today through innovative practice-changing clinical trials. Operationalizing this mission has required an enormous effort by our leaders, our staff, and our enrolling sites. As President, I am committed to continue to foster this outstanding culture in supporting our mission and to build upon our success, while conquering new challenges ahead for GOG-F and for our patients, who we are so honored to serve.”
Dr. Copeland observed: “Serving as President of GOG-F has been one of the greatest privileges of my career, and I am so pleased that the next President will be Dr. Thomas Herzog. Over the past many years, he has worked tirelessly on many fronts to advance our mission. He has demonstrated the vision and passion for clinical trials to transform the standard of care for women with gynecologic cancers. On completion of successful trials, he also exhibited a strong commitment to ‘getting the information out there’ through organizing and participating in informative educational programs. While serving as Immediate Past President, I pledge my full support to Tom in leading the GOG-F to continued success.”
